Abstract
Recently, we reported the successful use of the gVI-cDNA phage display technology to clone cDNAs coding for novel peroxisomal enzymes by affinity selection using immobilized antisera directed against peroxisomal subfractions (Fransen, M.; Van Veldhoven, P.P.; Subramani, S. Biochem. J., 1999, 340, 561-568). To identify other unknown peroxisomal enzymes, we further exploited this promising approach. Here we report the isolation and cloning of another novel human cDNA encoding a protein ending in the tripeptide AKL, a Cterminal peroxisomal targeting signal (PTS1). Primary structure analysis revealed that this molecule shared the highest sequence similarity to members of the 2,4-dienoyl-CoA reductase (DCR) family. However, functional analysis indicated that a recombinantly expressed version of the novel protein did not possess DCR activity with either 2-trans,4-trans-hexadienoyl-CoA or 2-trans,4-trans-decadienoyl-CoA as a substrate. The recombinant protein interacted with HsPex5p, the human PTS1-binding protein. Binding was competitively inhibited by a PTS1-containing peptide and was abolished when the last amino acid of the PTS1 signal was deleted. Transfection of mammalian cells with gene fusions between green fluorescent protein (GFP) and the human cDNA confirmed a peroxisomal localization and, therefore, the functionality of the PTS1. These results further demonstrate the suitability of the gVI-cDNA phage display technology for cDNA expression cloning using an antibody as a probe.
Combinatorial Chemistry & High Throughput Screening
Title: Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Volume: 4 Issue: 7
Author(s): L. Amery, G. P. Mannaerts, S. Subramani, P. P. Van Veldhoven and M. Fransen
Affiliation:
Abstract: Recently, we reported the successful use of the gVI-cDNA phage display technology to clone cDNAs coding for novel peroxisomal enzymes by affinity selection using immobilized antisera directed against peroxisomal subfractions (Fransen, M.; Van Veldhoven, P.P.; Subramani, S. Biochem. J., 1999, 340, 561-568). To identify other unknown peroxisomal enzymes, we further exploited this promising approach. Here we report the isolation and cloning of another novel human cDNA encoding a protein ending in the tripeptide AKL, a Cterminal peroxisomal targeting signal (PTS1). Primary structure analysis revealed that this molecule shared the highest sequence similarity to members of the 2,4-dienoyl-CoA reductase (DCR) family. However, functional analysis indicated that a recombinantly expressed version of the novel protein did not possess DCR activity with either 2-trans,4-trans-hexadienoyl-CoA or 2-trans,4-trans-decadienoyl-CoA as a substrate. The recombinant protein interacted with HsPex5p, the human PTS1-binding protein. Binding was competitively inhibited by a PTS1-containing peptide and was abolished when the last amino acid of the PTS1 signal was deleted. Transfection of mammalian cells with gene fusions between green fluorescent protein (GFP) and the human cDNA confirmed a peroxisomal localization and, therefore, the functionality of the PTS1. These results further demonstrate the suitability of the gVI-cDNA phage display technology for cDNA expression cloning using an antibody as a probe.
Export Options
About this article
Cite this article as:
Amery L., Mannaerts P. G., Subramani S., Van Veldhoven P. P. and Fransen M., Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology, Combinatorial Chemistry & High Throughput Screening 2001; 4 (7) . https://dx.doi.org/10.2174/1386207013330832
DOI https://dx.doi.org/10.2174/1386207013330832 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute-force experimentation, which can be time-consuming and resource-intensive. Spectral graph theory, a branch of mathematics dealing with the properties of graphs in relation to the eigenvalues and eigenvectors of matrices associated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Correlation between High Incidence of Colorectal Neoplastic Polyps and High-risk Adenomas in Patients with Diabetes Mellitus: A Retrospective Study
Endocrine, Metabolic & Immune Disorders - Drug Targets RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Cancer-associated Cachexia, Reactive Oxygen Species and Nutrition Therapy
Current Medicinal Chemistry Cancer Stem Cells and Colorectal Cancer: An Overview
Current Topics in Medicinal Chemistry Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design Editorial [Hot Topic:Targeted Therapeutics – From Chemical Structures to Diagnostic and Therapeutic Agents(Executive Editor: Christine Armbruster)]
Current Pharmaceutical Design Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry Therapeutic and Diagnostic Agents based on Bioactive Endogenous and Exogenous Coordination Compounds
Current Medicinal Chemistry